Physician profile
Michele Foeks
NPI 1699960450
$2,182.60
in general payments reported to CMS, 2019-2025
21 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $514 · 2023: $262 · 2024: $490 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $348.04 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $242.17 | 2021-2025 | |
| Boston Scientific Corporation | $191.66 | 2022-2024 | Watchman Access System, Watchman |
| Pfizer INC. | $185.45 | 2022-2024 | |
| Amgen INC. | $173.53 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $150.73 | 2025 | Wegovy |
| Abbott Laboratories | $124.48 | 2022-2025 | Cardiomems |
| Inspire Medical Systems, INC. | $119.88 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $117.40 | 2021-2024 | Lokelma, Wainua, Farxiga |
| Medtronic, INC. | $96.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.99 | 2022-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $69.39 | 2022 | |
| Merck Sharp & Dohme LLC | $68.18 | 2022-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $49.49 | 2023-2025 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $47.08 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $26.35 | 2025 | Ecc Solutions |
| Janssen Pharmaceuticals, INC | $23.98 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $22.49 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.08 | 2025 | Amvuttra |
| Abiomed | $18.28 | 2023 | Impella |
| Esperion Therapeutics, INC. | $16.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Foeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.